Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Share News (ORPH)

  • There is currently no data for ORPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM-Listed Firms Open Orphan And hVIVO Set For Tie-Up

Mon, 09th Dec 2019 11:23

(Alliance News) - Open Orphan PLC and hVIVO PLC on Monday said they have agreed terms on a reverse takeover, which would value the latter at GBP13.0 million.

Under the terms of the agreement, hVIVO shareholders will receive 2.47 new Open Orphan shares per hVIVO share. The deal values hVIVO shares at 15.56 pence each, a 34% premium to the clinical development services company's closing price of 11.62p on Friday.

hVIVO shares were trading 3.2% higher at 12.00p each in London on Monday morning. Drug consulting firm Open Orphan, also listed in London, was 13% lower at 5.00p each.

As the tie-up is deemed a reverse acquisition, Open Orphan needs the approval of its shareholders at a January 6 general meeting to confirm the deal.

Open Orphan said it expects to issue 205.5 million shares under the terms of the merger, with hVIVO shareholders owning just shy of 45% of the enlarged firm.

Open Orphan said: "Open Orphan and hVIVO are AIM-quoted groups that share a similar vision for the future of European Clinical Research Organisations and an entrepreneurial approach to developing further their business through a focus on operational efficiency, organic growth and targeted acquisitions to expand their geographic and service capabilities.

"The Open Orphan directors and the hVIVO directors believe that the combination of the businesses will result in synergies across the enlarged group with each business providing complementary services with limited overlap in existing capabilities and customers."

hVIVO's directors, which have backed the offer, hold a 0.3% stake in the company. Open Orphan shareholders, with an interest totalling roughly 30% of the firm, have also supported the tie-up.

Open Orphan Chief Executive Cathal Friel said: "The merger of Open Orphan and hVIVO is a key milestone in the execution of our strategy to become a larger-scale specialist pharma services business and in complementary segments where specialist skills and know-how command higher margins.

"The merger allows the combined business to maximise shareholder value through delivering cost and revenue synergies across the businesses and one that is better positioned to consistently capture greater market share as part of a properly profitable business with losses confined to the past."

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

More News
11 Nov 2019 16:29

Open Orphan inks preferred partner deal with Ipsen Group

(Sharecast News) - Europe-focussed rare and orphan drug consulting services platform Open Orphan announced the signing of a preferred partner agreement with Ipsen Group on Monday.

Read more
11 Nov 2019 13:48

Open Orphan Inks Venn Life Preferred Partner Agreement With Ipsen

Open Orphan Inks Venn Life Preferred Partner Agreement With Ipsen

Read more
15 Oct 2019 13:11

Open Orphan Inks Health Data Platform Deal With Empiric Logic

Open Orphan Inks Health Data Platform Deal With Empiric Logic

Read more
15 Oct 2019 11:13

Open Orphan signs deal with Empiric Logic to complete Health Data platform

(Sharecast News) - Europe-focussed rare and orphan drug consulting services platform provider Open Orphan has signed a new strategic collaboration agreement with Empiric Logic, it announced on Tuesday, to build on the earlier work it had performed, and complete the build out of its 'Health Data' platform as Europe's first rare disease, advocacy-led genomic database.

Read more
25 Sep 2019 11:51

Open Orphan Loss Widens On Venn Life Sciences Combination Cost

Open Orphan Loss Widens On Venn Life Sciences Combination Cost

Read more
1 Aug 2019 17:37

Open Orphan Names Ex-Horizon Therapeutics Director As Non-Executive

(Alliance News) - Drug consulting platform Open Orphan PLC said on Thursday that it has appointed David Kelly as an independent non-executive director.Kelly, the company said, has orphan in

Read more
12 Jul 2019 11:57

Open Orphan Divests Remaining 3.1% Stake In Integumen

(Alliance News) - Open Orphan PLC has netted over GBP500,000 after selling the rest of its shares in skin-care firm Integumen PLC, Open Orphan said on Friday.The sale of the 30.1 million on

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.